• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Cardiology

Esmolol-induced heart rate reduction may aid in septic shock

byAndrew Bishara
October 11, 2013
in Cardiology, Infectious Disease, Surgery
Reading Time: 4 mins read
Esmolol-induced heart rate reduction may aid in septic shock
Share on FacebookShare on Twitter

Image: PD

1. Patients in septic shock who received esmolol achieved reductions in heart rate to target levels without an associated increase in adverse events.

2. The 28-day mortality rate was 49.4% among patients receiving esmolol compared to 80.5% among patients receiving standard care (p<.001). 

Evidence Rating Level: 1 (Excellent)

Study Rundown: Septic shock, a low resistance, high-cardiac output state, is associated with excessive sympathetic outflow. Adrenergic stress has numerous well-documented adverse effects on critically ill patients, including increased cardiac workload and myocardial oxygen demand as well as direct cardiomyocyte toxicity from circulating catecholamines. Despite this, treating tachycardia in septic shock is controversial and norepinephrine remains the standard of care for sepsis-related hypotension. This trial aimed to test the hypothesis that intravenous beta blockade titrated to achieve heart rate control in septic shock represents an effective approach to enhance myocardial function and improve outcome without increased complications.

The study concluded that patients in septic shock who receive esmolol, a short-acting beta blocker, achieve target level heart rates without an increase in adverse events.  It is unclear how much of the mortality improvement seen in the esmolol group is due to heart rate reduction alone vs other noncardiac effects of beta blockade. Further research is necessary to determine whether outcomes are further improved with an individualized approach titrated to specific myocardial characteristics rather than a somewhat arbitrary predefined heart rate threshold. Future, larger trials are also necessary to determine the generalizability of results and the magnitude of effect in a population beyond this small sample size of septic patients preselected for their tachycardia and significant norepinephrine requirement.

RELATED REPORTS

Carvedilol linked to lower cirrhosis complication risk

Mezagitimab appears safe and potentially effective for persistent immune thrombocytopenia

Next-generation yellow fever vaccine shows comparable efficacy to standard vaccine

Click to read the study in JAMA

Click to read an accompanying editorial in JAMA

Relevant Reading: Mechanisms of sepsis-induced cardiac dysfunction

In-Depth [randomized, phase 2 study]: This study aimed to investigate the effect of a short-acting beta blocker in patients with severe septic shock.  Study participants included 154 patients in a university hospital intensive care unit (ICU) between 2010 and 2012 who had septic shock with a heart rate of at least 95 beats per minute and required high-dose norepinephrine to maintain mean arterial pressure of at least 65 mmHg. Seventy-seven patients were randomly assigned to receive continuous infusion of esmolol titrated to maintain a heart rate between 80 and 94 beats per minutes, whereas the remaining 77 received standard treatment. The primary outcome evaluated was heart rate control between 80 and 94 beats per minute. Secondary outcomes included the effect of esmolol on hemodynamic and organ function measures; norephinephrine requirements over a 96 hour period; and adverse events within 28 days of randomization.

All patients in the esmolol group achieved target heart rates, with a mean reduction of 18 beats per minute. As compared to patients receiving standard treatment, the esmolol group had increased stroke volume, systemic vascular resistance, and left ventricular stroke work indices. MAP was maintained in the esmolol group despite a significant reduction in norepinephrine (p=.003) and fluid (p<.001) requirements. Kidney function as measured by estimated glomerular filtration rate was better maintained (p<.001) and markers of myocardial injury were lower (p=.002) in this group as well.  Twenty-eight day mortality was 49.4% in the esmolol group vs 80.5% in the control group (95% CI, 0.26 to 0.59; P < .001).

By Elizabeth Kersten and Andrew Bishara

More from this author: Outreach increases colorectal cancer screening among underserved; Clinical impression not reliable in identifying drug-seeking behavior; Industry influences on expert panels contribute to over-diagnosis; Undervaccination becoming more common, associated with increased patient admission rates; Overuse of colonoscopy widespread in the US; Silent myocardial infarctions more common than previously assumed

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: beta blockercardiomyocyte toxicitycatecholaminesesmololheart ratephase 2 clinical trialseptic shock
Previous Post

The NASCET: Carotid endarterectomy for symptomatic stenosis [Classics Series]

Next Post

Clinical score effective in treating sore throat

RelatedReports

Increasing survival rates for patients with acute liver failure
Gastroenterology

Carvedilol linked to lower cirrhosis complication risk

July 6, 2026
New genetic link in pulmonary arterial hypertension holds therapeutic promise
Hematology

Mezagitimab appears safe and potentially effective for persistent immune thrombocytopenia

April 9, 2026
Medical vaccine exemptions increase after elimination of nonmedical exemptions
Infectious Disease

Next-generation yellow fever vaccine shows comparable efficacy to standard vaccine

April 8, 2026
Dacomitinib may be effective in EGFR-associated lung cancer
Oncology

Safety and efficacy profile of first-in-class oral p53 reactivator rezatapopt

March 3, 2026
Next Post
Clinical score effective in treating sore throat

Clinical score effective in treating sore throat

Shortage of evidence assessing teratogenic drugs

Shortage of evidence assessing teratogenic drugs

Hepatocellular carcinoma screening reduces mortality [Classics Series]

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Rimegepant (Nurtec ODT) may be an effective alternative to triptans for symptom relief in migraines
  • Dexmedetomidine (Precedex) may offer similar analgesic efficacy as remifentanil (Ultiva) with fewer adverse effects in adults undergoing sleeve gastrectomy
  • The Scan by 2 Minute Medicine®: Sugary drinks track with higher depression risk while coffee shows the opposite, US measles cases reach their highest level in decades, peptide injections fuel the next wellness craze, and most routine blood tests do not require prolonged fasting
License Content
Terms of Use | Disclaimer
Cookie Policy
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.